Patient demographics and clinicopathological data.

<p>Abbreviations: CIS, carcinoma in situ; IQR, interquartile range; SD, standard deviation.</p>a<p>n = 221.</p>b<p>Percentage of patients excluding those with stage T0 and Tx.</p>c<p>Percentage of recorded cases only.</p

Performance of Mcm5 and NMP22 tests for bladder carcinoma detection for all patients with test results available.

<p>Abbreviations: CI, 95% confidence interval; NPV, negative predictive value; PPV, positive predictive value; Sens, sensitivity; Spec, specificity.</p

Receiver operating characteristics curves for Mcm5 and NMP22 tests for the detection of bladder cancer in all studied patients with valid test results.

<p>Receiver operating characteristics curves for Mcm5 and NMP22 tests for the detection of bladder cancer in all studied patients with valid test results.</p

Comparison of Mcm5 and NMP22 test performance across grade and stage.

<p>Abbreviations: CI, 95% confidence interval; IQR, interquartile range; med, median; FNR, false negative rate.</p>a<p>Mann-Whitney test (for Test value) or Chi-squared test (for FNR), comparison with Normal group.</p>b<p>Mann-Whitney test (for Test value) or Chi-squared test (for FNR), comparison with previous, i.e. Grade 2 vs Grade 1, Grade 3 vs Grade 2.</p>c<p>Jonckheere-Terpstra test for trend (for Test value) or Chi-squared test for linear by linear association, across Grade or Stage, excluding Normal group.</p>d<p>Data analysis using 2150-cell cut-point for Mcm5 test.</p>e<p>Excludes 8 CIS and 1 adenocarcinoma from 210 UCC cases having an MCM5 test value.</p>f<p>Data analysis using 10 U/mL cut-point for NMP22 test.</p>g<p>Excludes 7 CIS from the 195 UCC cases having an NMP22 test value.</p

False positive rates for the Mcm5 and NMP22 tests across benign conditions.

<p>For each subgroup, only those patients with a test results were considered.</p><p>Abbreviations: BPH, benign prostatic hyperplasia; FPR, false positive rate; IQR, interquartile range; med, median; UTI, urinary tract infection.</p>a<p>Mann-Whitney test, comparison of test value with normal.</p>b<p>False positive rate determined using 2150-cell cut-point for Mcm5 test and 10 U/mL cut-point for NMP22 test.</p>c<p>Chi-squared test, comparison of false positive rate with Normal group.</p>d<p>Excludes 53 “other cancers” of the 1354 patients without UCC having an Mcm5 test value.</p>e<p>Excludes 47 “other cancers” of the 1201 patients without UCC having an NMP22 test value.</p